logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban] and Determine Cost of Therapy with invasive or Conservative strategy) - TIMI 18 trial.

    Article - En anglais

    Concern over escalating health care costs has led to increasing focus on economics and assessment of outcome measures for expensive forms of therapy.

    This is being investigated in the Treat Angina With Aggrastat [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS) - TIMI 18 trial, a randomized trial comparing outcome of patients with unstable angina or non-Q-wave myocardial infarction treated with tirofiban and then randomized to an invasive versus a conservative strategy.

    Hospital and professional costs initially and over 6 months, including outpatient costs, will be assessed.

    Hospital costs will be determined for patients in the United States from the UB92 formulation of the hospital bill, with costs derived from charges using departmental cost to charge ratios.

    Professional costs will be determined by accounting for professional services and then converted to resource units using the Resource Based Relative Value Scale and then to costs using the Medicare conversion factor.

    Follow-up resource consumption, including medications, testing and office visits, will be carefully measured with a Patient Economic Form, and converted to costs from the Medicare fee schedule.

    Health-related quality of life will be assessed with a specific instrument, the Seattle Angina Questionnaire, and a general instrument, the Health Utilities Index at baseline, 1, and 6 months.

    The Health Utilities Index will also be used to construct a utility. (...)

    Mots-clés Pascal : Angine poitrine, Tirofiban, Analyse coût efficacité, Economie santé, Qualité vie, Chimiothérapie, Traitement, Pronostic, Homme, Inhibiteur thromboagrégation, Appareil circulatoire pathologie, Cardiopathie coronaire

    Mots-clés Pascal anglais : Angina pectoris, Tirofiban, Cost efficiency analysis, Health economy, Quality of life, Chemotherapy, Treatment, Prognosis, Human, Antiplatelet agent, Cardiovascular disease, Coronary heart disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0124682

    Code Inist : 002B02G. Création : 16/11/1999.